Metoprolol is one of the most commonly prescribed medications for atrial fibrillation, and yes, it helps. It works by slowing your heart rate during AFib episodes, often bringing it down from around 140 beats per minute to roughly 80 to 90. What it does not do is restore a normal rhythm or prevent strokes, so it’s important to understand exactly what role it plays.
How Metoprolol Works During AFib
During atrial fibrillation, the upper chambers of your heart fire chaotic electrical signals. Many of those signals reach the lower chambers (the ventricles), which causes the fast, irregular heartbeat you feel as palpitations, breathlessness, or fatigue. Metoprolol blocks the effect of adrenaline on the heart, specifically targeting receptors in the heart’s electrical system. This slows down how quickly electrical signals pass from the upper chambers to the lower chambers, reducing the rate at which your ventricles beat.
It also extends the “rest period” between heartbeats by increasing the time cardiac cells need before they can fire again. The net result: your heart rate drops, your heart works less hard, and it demands less oxygen. For many people with AFib, this alone makes a significant difference in how they feel day to day.
What the Numbers Show
In clinical studies, metoprolol reduced the average 24-hour heart rate from about 96 beats per minute (untreated) to roughly 82 bpm. That’s a meaningful drop, though it was slightly less than what diltiazem, a calcium channel blocker, achieved (75 bpm). Both medications significantly lowered heart rate compared to no treatment, and the 2023 guidelines from the American Heart Association, American College of Cardiology, and Heart Rhythm Society recognize both as standard options for rate control in AFib.
In the largest head-to-head comparison to date, 200 patients with rapid AFib received either intravenous metoprolol or diltiazem. Rate control was achieved in 35% of the metoprolol group and 41% of the diltiazem group, a difference that was not statistically significant. Average time to rate control was also similar: 35 minutes for metoprolol versus 21 minutes for diltiazem. Neither medication clearly outperformed the other, and no patient-specific factors predicted which one would work better for a given person.
Rate Control vs. Rhythm Control
This is a distinction worth understanding clearly. Metoprolol is a rate control drug. It slows your heart rate during AFib, but it doesn’t stop the irregular rhythm itself. Your heart’s upper chambers may still fibrillate, and you may still be “in AFib” while taking it. The goal is simply to keep the ventricular rate manageable.
A major question in AFib treatment has been whether it’s better to control the rate (let AFib continue but keep the heart rate reasonable) or restore and maintain a normal rhythm with other medications or procedures. A meta-analysis of five large trials found that rate control and rhythm control produced comparable outcomes for most patients. In other words, keeping the heart rate under control with a drug like metoprolol is a perfectly valid long-term strategy, particularly for people with permanent AFib.
Heart Rate Targets
You might assume the goal is to get your resting heart rate as low as possible, but the evidence suggests otherwise. The RACE II trial randomly assigned 614 patients with permanent AFib to either strict rate control (resting heart rate below 80 bpm) or lenient rate control (resting heart rate below 110 bpm). Outcomes were similar in both groups. Many clinicians now aim for a resting heart rate under 110 bpm as a reasonable initial target, tightening that goal only if symptoms persist.
During exercise, targets are typically higher. Some guidelines use a cutoff of 110 bpm during a six-minute walk test, while others allow up to 140 bpm with moderate activity. Your target will depend on your symptoms and how well you tolerate the medication.
Two Forms of Metoprolol
Metoprolol comes in two formulations that behave quite differently. Metoprolol tartrate is the immediate-release version, typically taken twice daily. Metoprolol succinate is the extended-release version (often sold as Toprol-XL), taken once daily. For ongoing AFib management, the extended-release form provides more stable heart rate control throughout the day. In emergency settings where AFib pushes the heart rate dangerously high, metoprolol can be given intravenously, though it takes about 20 minutes to reach its full effect, compared to roughly 3 minutes for diltiazem.
Side Effects and Safety
Metoprolol is generally well tolerated. The most common side effects are fatigue, dizziness, and cold hands or feet, all related to its effect of slowing the heart and lowering blood pressure. A systematic review and meta-analysis found that metoprolol was associated with a 26% lower risk of adverse events (primarily slow heart rate and low blood pressure) compared to diltiazem, with an overall adverse event rate of about 10%.
People with asthma or severe chronic lung disease need to be cautious. Although metoprolol preferentially targets the heart rather than the lungs, at higher doses it can affect the airways and potentially trigger bronchospasm. For AFib patients with significant respiratory issues, a calcium channel blocker like diltiazem is often preferred. Metoprolol should also be avoided in people with very slow heart rates, certain types of heart block, or severely low blood pressure.
What Metoprolol Does Not Do
One critical point: metoprolol does not reduce your risk of stroke. AFib increases stroke risk because blood can pool in the fibrillating upper chambers and form clots. Metoprolol slows your heart rate, but it doesn’t address this clotting risk. If your stroke risk score warrants it, you’ll still need a blood thinner alongside metoprolol. These are two separate jobs, and metoprolol handles only one of them.
Keeping your heart rate controlled does, however, protect the heart muscle from long-term damage. A heart that beats too fast for too long can weaken over time, a condition called tachycardia-induced cardiomyopathy. By keeping the rate in check, metoprolol helps preserve heart function. In the large MERIT-HF trial, patients with heart failure who took extended-release metoprolol had fewer hospitalizations, better functional capacity, and improved overall well-being compared to those on placebo.
How Most People Feel on It
For many people with AFib, starting metoprolol brings noticeable relief. The racing, pounding sensation calms down. Breathlessness during routine activities often improves. Stanford Medicine notes that when beta blockers bring the heart rate from the 140s down to around 90, patients typically feel “much better and are able to be more active.” The improvement is often apparent within the first few days of finding the right dose, though it may take some adjustment to dial in the amount that controls your rate without making you feel sluggish or lightheaded.